Patent · US Active

Quinoline derivatives as P13 kinase inhibitors

US8404837B2 · kind B2 · utility

1Cited by

8References

9Claims

0Family size

Assignee

GlaxoSmithKline LLC · US

Inventors

Nicholas D. Adams · Royersford, US
Joelle Lorraine Burgess · Collegeville, US
Michael Gerard Darcy · Collegeville, US
Carla A. Donatelli · Collegeville, US
Steven David Knight · West Chester, US
Kenneth A. Newlander · West Chester, US
Lance Ridgers · Collegeville, US
Martha A. Sarpong · Collegeville, US
Stanley J. Schmidt · Chester Springs, US

Key dates

Filing date	May 16, 2008
Grant date	Mar 26, 2013
Priority date	—
Expiry date	Oct 18, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D498/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.